AFT Pharmaceuticals - Hikma partnership expands to include Combogesic
AFT Pharmaceuticals has expanded its licensing partnership with Hikma in the US to include distribution of the recently launched Combogesic tablets...
427 Views
AFT Pharmaceuticals. - Postcard From the UK
Over the past twelve months, AFT Pharmaceuticals (AFT) has launched its Maxigesic tablet into the UK (branded as Combogesic).
251 Views
AFT Pharmaceuticals - Continued execution of footprint expansion
AFT Pharmaceuticals continues to make inroads in expanding its strategic market footprint. Most recently, it announced the entry into China with...
253 Views
AFT Pharmaceuticals - FY24 Result — Roaring Revenue
We retain our OUTPERFORM rating with an unchanged target price of NZ$4.60 (roll forward and peers re-rate offsets earnings downgrades).
329 Views
AFT Pharmaceuticals - Growth underpinned by international momentum
AFT Pharmaceuticals’ FY24 results demonstrated record earnings and sales, with 24.8% year-on-year sales growth. Revenues of NZ$195.4m were driven...
322 Views